196 related articles for article (PubMed ID: 21785120)
1. Thimerosal exposure in early life and neuropsychological outcomes 7-10 years later.
Barile JP; Kuperminc GP; Weintraub ES; Mink JW; Thompson WW
J Pediatr Psychol; 2012; 37(1):106-18. PubMed ID: 21785120
[TBL] [Abstract][Full Text] [Related]
2. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years.
Thompson WW; Price C; Goodson B; Shay DK; Benson P; Hinrichsen VL; Lewis E; Eriksen E; Ray P; Marcy SM; Dunn J; Jackson LA; Lieu TA; Black S; Stewart G; Weintraub ES; Davis RL; DeStefano F;
N Engl J Med; 2007 Sep; 357(13):1281-92. PubMed ID: 17898097
[TBL] [Abstract][Full Text] [Related]
3. Neuropsychological performance 10 years after immunization in infancy with thimerosal-containing vaccines.
Tozzi AE; Bisiacchi P; Tarantino V; De Mei B; D'Elia L; Chiarotti F; Salmaso S
Pediatrics; 2009 Feb; 123(2):475-82. PubMed ID: 19171612
[TBL] [Abstract][Full Text] [Related]
4. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association.
Andrews N; Miller E; Grant A; Stowe J; Osborne V; Taylor B
Pediatrics; 2004 Sep; 114(3):584-91. PubMed ID: 15342825
[TBL] [Abstract][Full Text] [Related]
5. Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism.
Price CS; Thompson WW; Goodson B; Weintraub ES; Croen LA; Hinrichsen VL; Marcy M; Robertson A; Eriksen E; Lewis E; Bernal P; Shay D; Davis RL; DeStefano F
Pediatrics; 2010 Oct; 126(4):656-64. PubMed ID: 20837594
[TBL] [Abstract][Full Text] [Related]
6. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases.
Verstraeten T; Davis RL; DeStefano F; Lieu TA; Rhodes PH; Black SB; Shinefield H; Chen RT;
Pediatrics; 2003 Nov; 112(5):1039-48. PubMed ID: 14595043
[TBL] [Abstract][Full Text] [Related]
7. Neonatal exposure to Thimerosal from vaccines and child development in the first 3 years of life.
Mrozek-Budzyn D; Majewska R; Kieltyka A; Augustyniak M
Neurotoxicol Teratol; 2012; 34(6):592-7. PubMed ID: 23069197
[TBL] [Abstract][Full Text] [Related]
8. Continuing increases in autism reported to California's developmental services system: mercury in retrograde.
Schechter R; Grether JK
Arch Gen Psychiatry; 2008 Jan; 65(1):19-24. PubMed ID: 18180424
[TBL] [Abstract][Full Text] [Related]
9. Modeling neurodevelopment outcomes and ethylmercury exposure from thimerosal-containing vaccines.
Dórea JG; Marques RC
Toxicol Sci; 2008 Jun; 103(2):414-5; author reply 416. PubMed ID: 18364366
[No Abstract] [Full Text] [Related]
10. Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink.
Young HA; Geier DA; Geier MR
J Neurol Sci; 2008 Aug; 271(1-2):110-8. PubMed ID: 18482737
[TBL] [Abstract][Full Text] [Related]
11. Thimerosal disappears but autism remains.
Fombonne E
Arch Gen Psychiatry; 2008 Jan; 65(1):15-6. PubMed ID: 18180423
[No Abstract] [Full Text] [Related]
12. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data.
Parker SK; Schwartz B; Todd J; Pickering LK
Pediatrics; 2004 Sep; 114(3):793-804. PubMed ID: 15342856
[TBL] [Abstract][Full Text] [Related]
13. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United kingdom does not support a causal association.
Heron J; Golding J;
Pediatrics; 2004 Sep; 114(3):577-83. PubMed ID: 15342824
[TBL] [Abstract][Full Text] [Related]
14. Assessment of metallothionein and antibodies to metallothionein in normal and autistic children having exposure to vaccine-derived thimerosal.
Singh VK; Hanson J
Pediatr Allergy Immunol; 2006 Jun; 17(4):291-6. PubMed ID: 16771783
[TBL] [Abstract][Full Text] [Related]
15. Letter to the editor. The safety of thimerosal in newborn and infant vaccines.
Thompson WW; DeStefano F; Chen R
Vaccine; 2004 Dec; 23(3):281-2. PubMed ID: 15530668
[No Abstract] [Full Text] [Related]
16. [Thimerosal and the occurrence of autism. Negative ecological evidence from Danish registry-data].
Madsen KM; Lauritsen MB; Pedersen CB; Thorsen P; Plesner AM; Andersen PH; Mortensen PB
Ugeskr Laeger; 2004 Sep; 166(38):3291-3. PubMed ID: 15496004
[No Abstract] [Full Text] [Related]
17. Thimerosal exposure (from tetanus-diphtheria vaccine) during pregnancy and neurodevelopment of breastfed infants at 6 months.
Marques RC; Dórea JG; Bernardi JV
Acta Paediatr; 2010 Jun; 99(6):934-9. PubMed ID: 20003103
[TBL] [Abstract][Full Text] [Related]
18. Neurodevelopmental disorders following thimerosal-containing childhood immunizations: a follow-up analysis.
Geier D; Geier MR
Int J Toxicol; 2004; 23(6):369-76. PubMed ID: 15764492
[TBL] [Abstract][Full Text] [Related]
19. A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism.
Geier DA; Geier MR
Med Sci Monit; 2004 Mar; 10(3):PI33-9. PubMed ID: 14976450
[TBL] [Abstract][Full Text] [Related]
20. Global justice and the proposed ban on thimerosal-containing vaccines.
King K; Paterson M; Green SK
Pediatrics; 2013 Jan; 131(1):154-6. PubMed ID: 23248220
[No Abstract] [Full Text] [Related]
[Next] [New Search]
